

Myriad Genetics Inc. (MYGN)

Nasdaq; healthcare; SIC 2835, In Vitro & In Vivo Diagnostic Substances; CIK 0000899923

Myriad Genetics Inc. MYGN; healthcare	
Grade	B A B C D E second fifth of 371 graded peers percentile 28.4; sampling error 2.5 points; lower is stronger
Rank	106 of 371
Profitability	A percentile 8.8
Solvency	C/D percentile 58.6
Growth and financing	C percentile 56.0
Reliability	0.91 AUC filers with \$591M to \$2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025
Peer failure rate	1.01% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	\$591M to \$2.67B assets total assets \$706.6M
Standard universe	inside revenue above \$1M and assets above \$10M
Warnings	none active; fortress balance sheet not computable: distress
Inputs computable	7 of 14
Graded from	filings received through Feb 24, 2026 227 days before the rescans; latest periodic filing 10-Q received Jul 31, 2026
Last close	\$4.17 2026-10-08; market equity \$399.3M
Price used in grade	None



B, the elk
second fifth of its sector; letters are fifths of the 371 graded peers

Share price, twelve months to the rescans

split-adjusted close; the letter is fixed at the rescans that set it



Rescans on file: B/C from Mar 21, 2025, B from Dec 21, 2025, B/C from Feb 21, 2026, B from Mar 21, 2026

Letter at every rescans

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Feb 24, 2026

Myriad Genetics is a leading molecular diagnostics and precision medicine company committed to advancing health and well-being for all. We develop and commercialize molecular tests that help patients and providers uncover genetic insights. Our tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care, support earlier detection, enable more precise treatment and contribute to lowering healthcare

costs. Personalized molecular data and digital and virtual consumer trends are converging to transform traditional models of care.

The fourteen inputs


lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 8.8						
Gross profitability		81.6%	32.2%	7.8	372	2025-12-31
Return on invested capital		not computable	9.3%			prior invested-capital observation is 1096 days earlier
Accruals ratio		(42.4%)	(6.6%)	9.8	811	2025-12-31
Gross margin stability, five years		not computable	2.8 pts			five consecutive annual gross margins are required
Solvency, sleeve percentile 58.6						
Twelve-month failure probability		not computable	0.07%			latest liabilities, cash plus short-term investments, book equity, and shares are required
Altman Z double-prime		(5.88)	(0.31)	54.0	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			EBITDA must exceed \$100,000
Interest coverage		not computable	(4.51x)			latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31
Current ratio		2.49x	2.96x	63.2	839	2025-12-31
Growth and financing, sleeve percentile 56.0						
Revenue growth, three-year compound		6.7%	10.0%	56.0	415	2025-12-31
Free cash flow growth, three-year compound		not computable	10.9%			four consecutive annual FCF observations are required; found 12 NOPAT must exceed \$100,000
Reinvestment rate		not computable	37.1%			
Asset growth, three years		(16.2%)	2.1%	77.7	704	2025-12-31
Net share issuance, one year		2.4%	2.5%	34.3	634	2026-02-19

Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Fortress balance sheet	cash minus debt is 29,700,000 USD; Altman Z is not used



Rank	Company	Percentile	Letter	Warnings
101	Traverse Therapeutics, Inc. (TVTX)	27.0	B	
102	Tela Bio, Inc. (TELA)	27.3	B	fortress balance sheet
103	Alphatec Holdings, Inc. (ATEC)	27.6	B	
104	Agape ATP Corp. (ATPC)	27.8	B	late filer
105	Agios Pharmaceuticals, Inc. (AGIO)	28.1	B	short runway
106	Myriad Genetics Inc. (MYGN) <	28.4	B	fortress balance sheet
107	DocGo Inc. (DCGO)	28.6	B	late filer, fortress balance sheet
108	Healthcare Services Group Inc. (HCSG)	28.9	B	
109	Staar Surgical Co. (STAA)	29.2	B	
110	Cytokinetics Inc. (CYTK)	29.5	B	short runway
111	Steris plc (STE)	29.7	B	

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(55.5%)	8.0%	11
Distance from 52-week high	(48.7%)	(31.4%)	29
EBIT to enterprise value	(95.1%)	(1.5%)	7
Free cash flow yield	(37.7%)	(1.0%)	16
Book value to price	0.76	0.28	79
Sales to price	2.05	0.31	90
Composite equity issuance, five years	22.6%	20.3%	51
Relative strength against the sector, log excess return	(1.02)	(0.14)	11

Diagnostics

not in the grade

Measure	Value
Piotroski F-score 5 of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	pass
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	pass
Asset turnover improved	pass

Cash, filings, liquidity	
Cash and equivalents	\$115.2M
Operating cash flow, four quarters	\$7.7M
Months of runway	not finite
Days since last periodic filing	70 (10-Q received Jul 31, 2026)
Median daily dollar volume, 63 sessions	\$6.2M

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	\$576.6M	2025-12-31	2026-02-24	10-K	0000899923-26-000018
2	assets	us-gaap:Assets	\$706.6M	2025-12-31	2026-02-24	10-K	0000899923-26-000018
3	operating income	us-gaap:OperatingIncomeLoss	-\$387.2M	2025-12-31	2026-02-24	10-K	0000899923-26-000018
4	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsUnusualItems	-\$354.1M	2025-12-31	2026-02-24	10-K	0000899923-26-000018
5	income tax	us-gaap:IncomeTaxExpenseBenefit	-\$29.2M	2025-12-31	2026-02-24	10-K	0000899923-26-000018
6	total debt	us-gaap:LongTermDebt	\$119.9M	2025-12-31	2026-02-24	10-K	0000899923-26-000018
7	book equity	us-gaap:StockholdersEquity	\$368.0M	2025-12-31	2026-02-24	10-K	0000899923-26-000018
8	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$149.6M	2025-12-31	2026-02-24	10-K	0000899923-26-000018
9	total debt	us-gaap:LongTermDebt	\$0	2022-12-31	2023-03-01	10-K	0000899923-23-000011
10	book equity	us-gaap:StockholdersEquity	\$885.8M	2022-12-31	2026-02-24	10-K	0000899923-26-000018
11	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$56.9M	2022-12-31	2025-02-28	10-K	0000899923-25-000019
12	net income	us-gaap:NetIncomeLoss	-\$365.9M	2025-12-31	2026-02-24	10-K	0000899923-26-000018
13	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$1.8M	2025-12-31	2026-02-24	10-K	0000899923-26-000018
14	assets	us-gaap:Assets	\$1.0B	2024-12-31	2026-02-24	10-K	0000899923-26-000018
15	current assets	us-gaap:AssetsCurrent	\$332.6M	2025-12-31	2026-02-24	10-K	0000899923-26-000018
16	current liabilities	us-gaap:LiabilitiesCurrent	\$133.8M	2025-12-31	2026-02-24	10-K	0000899923-26-000018
17	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$1.1B	2025-12-31	2026-02-24	10-K	0000899923-26-000018
18	liabilities	us-gaap:Liabilities	\$338.6M	2025-12-31	2026-02-24	10-K	0000899923-26-000018
19	depreciation amortization	us-gaap:Depreciation	\$19.5M	2025-12-31	2026-02-24	10-K	0000899923-26-000018
20	operating income	us-gaap:OperatingIncomeLoss	-\$257.4M	2023-12-31	2026-02-24	10-K	0000899923-26-000018
21	interest expense	us-gaap:InterestExpense	\$2.9M	2023-12-31	2024-02-28	10-K	0000899923-24-000018
22	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$824.5M	2025-12-31	2026-02-24	10-K	0000899923-26-000018
23	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$837.6M	2024-12-31	2026-02-24	10-K	0000899923-26-000018
24	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$753.2M	2023-12-31	2026-02-24	10-K	0000899923-26-000018
25	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$678.4M	2022-12-31	2025-02-28	10-K	0000899923-25-000019
26	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	\$45.3M	2022-12-31	2023-03-01	10-K	0000899923-23-000011
27	depreciation amortization	us-gaap:Depreciation	\$11.6M	2022-12-31	2025-02-28	10-K	0000899923-25-000019
28	operating income	us-gaap:OperatingIncomeLoss	-\$140.6M	2022-12-31	2025-02-28	10-K	0000899923-25-000019
29	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsUnusualItems	-\$140.6M	2022-12-31	2025-02-28	10-K	0000899923-25-000019
30	income tax	us-gaap:IncomeTaxExpenseBenefit	-\$28.6M	2022-12-31	2025-02-28	10-K	0000899923-25-000019
31	current assets	us-gaap:AssetsCurrent	\$274.6M	2022-12-31	2024-02-28	10-K	0000899923-24-000018
32	current liabilities	us-gaap:LiabilitiesCurrent	\$137.2M	2022-12-31	2024-02-28	10-K	0000899923-24-000018
33	current assets	us-gaap:AssetsCurrent	\$484.8M	2021-12-31	2023-03-01	10-K	0000899923-23-000011
34	current liabilities	us-gaap:LiabilitiesCurrent	\$204.3M	2021-12-31	2023-03-01	10-K	0000899923-23-000011
35	assets	us-gaap:Assets	\$1.1B	2023-12-31	2025-02-28	10-K	0000899923-25-000019
36	assets	us-gaap:Assets	\$1.2B	2022-12-31	2024-02-28	10-K	0000899923-24-000018
37	shares outstanding	dei:EntityCommonStockSharesOutstanding	93,508,165	2026-02-19	2026-02-24	10-K	0000899923-26-000018
38	shares outstanding	dei:EntityCommonStockSharesOutstanding	91,309,064	2025-02-21	2025-02-28	10-K	0000899923-25-000019